Pacira BioSciences, Inc.
Pacira BioSciences is a US biopharmaceutical company focused on non-opioid pain management and regenerative health solutions.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Pacira BioSciences, Inc. is a publicly traded biopharmaceutical company whose commercial focus includes non-opioid pain management and regenerative health solutions. Founded in 2006, the company develops and markets pharmaceutical products and related technologies, with a particular emphasis on treatments intended to address pain and improve patient recovery. Its portfolio includes Exparel, a liposomal bupivacaine product used for postsurgical pain management; Zilretta, an extended-release corticosteroid injection for knee osteoarthritis pain; and iovera°, a device-based cryoneurolysis treatment for pain relief. Pacira’s products serve health-care providers and patients, with use spanning surgical pain management and musculoskeletal conditions. The company’s commercial model combines marketed products with ongoing product development and efforts to broaden the use of its therapies. Its stated areas of interest also include regenerative health, reflecting a wider ambition than a single-drug portfolio. Pacira is headquartered in Tampa, Florida, and its shares trade on Nasdaq under the symbol PCRX. It has operated under the Pacira BioSciences name since changing from Pacira Pharmaceuticals. The company competes in regulated pharmaceutical and medical technology markets, where adoption depends on clinical evidence, product labeling, reimbursement, and provider practice. Its positioning centers on non-opioid approaches to pain care and products designed to provide alternatives or complements to conventional pain-management methods.
History
Pacira BioSciences was established in 2006 as a biopharmaceutical company and built its business around pharmaceutical approaches to pain management. The company was initially known as Pacira Pharmaceuticals. Its subsequent development has combined commercial products with research and development intended to expand its offerings in pain care and related health areas. A significant part of the company’s commercial profile is Exparel, a liposomal formulation of bupivacaine used for postsurgical pain management. The product helped define Pacira’s emphasis on long-acting, local, non-opioid pain treatment. The company later added Zilretta, an extended-release triamcinolone acetonide injection for knee osteoarthritis pain, and iovera°, a cryoneurolysis technology used to provide targeted pain relief. These products give Pacira a portfolio spanning drug products and a device-based treatment approach. The company adopted the Pacira BioSciences name, reflecting a broader corporate identity than its former Pacira Pharmaceuticals name. It has also described its interests in terms of regenerative health solutions alongside non-opioid pain management. Pacira is headquartered in Tampa, Florida, and is publicly traded on Nasdaq as PCRX. Its business operates in highly regulated markets and depends on product approvals, clinical evidence, commercial execution, and the adoption of its offerings by health-care professionals and institutions. Pacira’s history is therefore characterized by the development and commercialization of differentiated pain-management products, expansion beyond a single product into a multi-offering portfolio, and a continuing effort to position the company around non-opioid care and regenerative health. Specific corporate milestones beyond these broad developments are not included here where reliable dates or details are not established by the supplied evidence.
- 2006
Company founded
Adopted the Pacira BioSciences name
Products and positioning
A commercial biopharmaceutical company differentiated by non-opioid pain-management products and a broader regenerative-health focus.
Exparel
Liposomal bupivacaine injectable suspension used for postsurgical pain management.
Zilretta
Extended-release triamcinolone acetonide injectable suspension for knee osteoarthritis pain.
iovera°
Cryoneurolysis technology used for targeted pain relief.
Recent events
- Unconfirmed
Viatris acquires Pacira BioSciences for $1.65 billion[2]
Viatris Inc. has acquired Pacira BioSciences, Inc.'s outstanding common stock shares for $36.50 per share in cash, in a $1.65 billion transaction. Law firm Ashurst Perkins Coie, which served as main counsel throughout the transaction process, advised Pacira. Viatris plans to extend product lifecycles, sustain meaningful sales, and expand the Pacira products' reach across select markets within its global infrastructure.
Pacira BioSciences reports second-quarter 2021 results[3]
Reported:
Pacira BioSciences reported second-quarter 2021 financial results, including record revenue of $135.6 million and GAAP net income of $19.1 million.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/pacira-biosciences-inc · Editorial policy · How profiles are compiled